Manso, Luis <br/><br/>
Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.  [electronic resource] 

 -  The breast journal  03 2019 
 - 219-225 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1524-4741 
<br/><br/><label>Standard No.: </label>10.1111/tbj.13199  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Anthracyclines--administration & dosage<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Female<br/>Furans--adverse effects<br/>Humans<br/>Ketones--adverse effects<br/>Middle Aged<br/>Neoplastic Cells, Circulating<br/>Prospective Studies<br/>Receptor, ErbB-2--metabolism<br/>Taxoids--administration & dosage